Brad Dahms

Brad Dahms is Chief Financial Officer of Theseus Pharmaceuticals. Brad most recently served as Chief Financial Officer of Selecta Biosciences, Inc. (NASDAQ: SELB), where he oversaw financial operations, investor relations, and business development activities. He led Selecta through several significant financing and strategic transactions, including a $730 million licensing agreement. Previously, Brad was a Senior Vice President in the Healthcare Group at Cantor Fitzgerald & Co., focused on providing strategic and financial advice to life sciences companies. Prior to Cantor, Brad held several other investment banking roles, including at RBC Capital Markets in the Healthcare Group, and at J.P. Morgan. Brad earned a B.S. in Economics, with honors, from The Ohio State University.